What is the 13F Pro Quality Score for SXTP?

13F Pro ranks 60 DEGREES PHARMACEUTICALS, INC. (SXTP) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View SXTP's current score at https://13fpro.ai/research/SXTP (free sign-up required for the full ranking).

Where does 13F Pro source SXTP data?

All 60 DEGREES PHARMACEUTICALS, INC. fundamentals and ownership data come directly from SEC EDGAR. 60 DEGREES PHARMACEUTICALS, INC. files with the SEC under CIK 1946563. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is SXTP in?

60 DEGREES PHARMACEUTICALS, INC. (SXTP) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

How often is SXTP research updated on 13F Pro?

SXTP's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

60 DEGREES PHARMACEUTICALS, INC.(SXTP)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →Nasdaq

Institutional-grade research for retail investors

SEC EDGAR: CIK 1946563 SXTP stock profile & AI dashboard →

13F Pro Quality Score

Not in ranked universe

Below size threshold

Quality rankings require at least $50M annual revenue or $250M total assets to filter out micro-caps and shell companies. This company reported $1.0M in revenue.

Financial data, filings, and institutional holdings below are still tracked in full — only the proprietary quality composite is unavailable for this name.

SXTP Stock Analysis & AI Quality Score

AI stock analysis and institutional research for 60 DEGREES PHARMACEUTICALS, INC. (SXTP), a Healthcare sector company. SXTP is not currently included in 13F Pro's AI-ranked quality universe — quality rankings require at least $50m annual revenue or $250m total assets to filter out micro-caps and shell companies. this company reported $1.0m in revenue. Based on the latest XBRL financial filings (Q1 2026), 60 DEGREES PHARMACEUTICALS, INC. reports quarterly revenue of $162.1K, net income of $-2.1M, free cash flow of $-2.8M. Top institutional holders of SXTP by reported 13-F value include Kathmere Capital Management,, UBS Group AG, GEODE CAPITAL MANAGEMENT,, based on the most recent SEC filings. SXTP trades on the Nasdaq exchange and files with the SEC under CIK 1946563. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate SXTP daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for 60 DEGREES PHARMACEUTICALS, INC. directly from SEC EDGAR.

Revenue

Q1 2026

$162.1K

Net Income

Q1 2026

$-2.1M

Free Cash Flow

Q1 2026

$-2.8M

D/E Ratio

Q1 2026

0.03

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro+

Revenue

+65.5% YoY

$1.0MFY 2025

FY22 $223.2KFY23 $253.6KFY24 $607.6KFY25 $1.0M

Net Income

+7.3% YoY

$-7.4MFY 2025

FY22 $-6.2MFY23 $-3.8MFY24 $-7.9MFY25 $-7.4M

Operating Income

+20.1% YoY

$-7.8MFY 2025

FY22 $-1.8MFY23 $-5.2MFY24 $-9.7MFY25 $-7.8M

EPS (Diluted)

+84.2% YoY

$-11.73FY 2025

FY22 $-0.50FY23 $-11.27FY24 $-74.17FY25 $-11.73

Total Assets

-6.8% YoY

$5.4MFY 2025

FY22 $1.3MFY23 $7.8MFY24 $5.8MFY25 $5.4M

Total Debt

+0.0% YoY

$158.8KFY 2025

FY22 $16.9MFY23 $158.8KFY24 $158.8KFY25 $158.8K

Op. Cash Flow

-21.3% YoY

$-6.8MFY 2025

FY22 $-1.0MFY23 $-4.5MFY24 $-5.6MFY25 $-6.8M

Metric	FY 2025	FY 2024	FY 2023	FY 2022
Revenue	$1.0M +65.5%	$607.6K +139.6%	$253.6K +13.6%	$223.2K
Net Income	$-7.4M +7.3%	$-7.9M -111.0%	$-3.8M +39.1%	$-6.2M
Operating Income	$-7.8M +20.1%	$-9.7M -88.5%	$-5.2M -194.5%	$-1.8M
EPS (Diluted)	$-11.73 +84.2%	$-74.17 -558.0%	$-11.27 -2167.6%	$-0.50
Total Assets	$5.4M -6.8%	$5.8M -26.0%	$7.8M +500.0%	$1.3M
Total Debt	$158.8K +0.0%	$158.8K +0.0%	$158.8K -99.1%	$16.9M
Operating Cash Flow	$-6.8M -21.3%	$-5.6M -24.3%	$-4.5M -349.8%	$-1.0M

AI Insight: SXTP Financial Trends

Pre-revenue biotech with persistent quarterly losses and deteriorating cash burn despite debt elimination.

• Revenue remains at $0M across all eight quarters (Q2 2024–Q1 2026); company has not achieved commercial sales.

• Operating losses stable at $2M per quarter; net losses narrowed to $1M in Q4 2025 but widened back to $2M in Q1 2026.

• Total debt eliminated: fell from $3M (Q2–Q3 2024) to $0M by Q1 2025, remaining at $0M through Q1 2026.

• Operating cash flow deteriorated to $3M negative burn in Q1 2026, worst quarter in the period.

⚠ Equity volatility: oscillated between $2M–$6M; now at $5M in Q1 2026 after dip to $2M in Q2 2025.

⚠ Accelerating cash burn in Q1 2026 ($3M operating outflow) signals runway risk absent imminent revenue inflection.

AI Insight: SXTP Ratio Trends

60 Degrees Pharmaceuticals remains deeply unprofitable with negative ROE consistently between -143% and -183%, though leverage has compressed sharply from 1.04x to 0.03x.

• Debt-to-equity collapsed from 1.04x in Q2 2024 to 0.03x in TTM 2026—a 97% reduction in financial leverage.

• ROE remained severely negative across all reported quarters (Q3 2024 through Q1 2026), ranging from -143.0% to -182.6%.

⚠ Company has generated no reportable operating margin, net profit margin, or ROIC data—indicating sustained losses without disclosed operational metrics.

⚠ TTM ROE of -156.9% suggests cumulative 12-month profitability remains severely negative despite deleveraging progress.

Get alerted when SXTP's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for 60 DEGREES PHARMACEUTICALS, INC. including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of SXTP

Kathmere Capital Management, LLC
$253.2K144,683 sh
UBS Group AG
$55.0K31,410 sh
GEODE CAPITAL MANAGEMENT, LLC
$28.5K16,295 sh
BARCLAYS PLC
$3.2K1,856 sh
OSAIC HOLDINGS, INC.
$43.0025 sh
TWIN PEAKS WEALTH ADVISORS, LLC
$14.008 sh
CITIGROUP INC
$2.001 sh

Fund	Value	Shares
Kathmere Capital Management, LLC	$253.2K	144,683
UBS Group AG	$55.0K	31,410
GEODE CAPITAL MANAGEMENT, LLC	$28.5K	16,295
BARCLAYS PLC	$3.2K	1,856
OSAIC HOLDINGS, INC.	$43.00	25
TWIN PEAKS WEALTH ADVISORS, LLC	$14.00	8
CITIGROUP INC	$2.00	1

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put SXTP on your watchlist

Track score changes the day 60 DEGREES PHARMACEUTICALS, INC. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is SXTP a good stock to buy?

13F Pro's AI-powered analysis of 60 DEGREES PHARMACEUTICALS, INC. (SXTP) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for SXTP are available on the SXTP stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.

Which hedge funds own SXTP?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling SXTP. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of 60 DEGREES PHARMACEUTICALS, INC.'s investment landscape.